Current state of upfront treatment for newly diagnosed advanced ovarian cancer
|
|
- Kenneth Page
- 6 years ago
- Views:
Transcription
1 Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute Boston, MA Phone:
2 Agenda Review trials for upfront management of newly diagnosed advanced ovarian cancer Review ongoing studies Review new therapies being tested
3 Ovarian cancer ,500 cases diagnosed per year in the United States and 16,500 deaths per year 1. Most patients are diagnosed in late stages; no screening test exists. Pathology: 4 different types (serous, endometrioid,, clear cell and mucinous) 1 Jemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
4 Unique aspects of newly diagnosed advanced ovarian cancer Upfront surgical management is standard of care: allows access to tissue OC is very chemotherapy sensitive at diagnosis; >80% of cancers will respond to platinum- and taxane-based chemotherapy upfront at dx. Cancer becomes more treatment-refractory refractory following recurrence. Few but some CTC s. Outcomes for newly diagnosed ovarian cancer have reached a plateau with platinum/taxane taxane combinations.
5 Ovarian cancer staging Stage I: confined to ovary(ies) Stage II: local spread to pelvis Stage III: Stage IIIA: microscopic upper abdominal spread Stage IIIB: upper abd implants <2 cm Stage IIIC: 2cm implants and/or +nodal involvement Stage IV: spread outside the abdominal cavity. Definition of extent of debulking is what is residual post surgical debulking: optimal cytoreduction/debulking: 1cm residual suboptimal debulking: : > 1cm residual cancer
6 Advanced ovarian cancer
7 PFS and OS for newly diagnosed advanced ovarian cancer Study Median PFS Median OS Comments GOG 111 NEJM mos 38 mos Suboptimally and stage IV GOG 158 JCO mos 57.4 mos Optimally cytoreduced only GOG 172 NEJM mos 65 mos Optimally cytoreduced only. Longest survival observed in advanced ovarian cancer GOG 182 JCO mos 44 mos Both optimal and suboptimal. Study compared 5 arms of treatment Weekly pac vs q21 d Lancet mos (vs. 17 mos) Not reached Both optimal and suboptimal EORTC neoadjuvant IGCS 2008 Both 12 mos 29/30 mos Neoadjuvant vs. upfront debulking GOG 218: ASCO 2010
8 GOG111: Survival By Treatment Pac + cis (38 mos) Cy + cis (24 mos) Treatment Alive (N) Died (N) Median PFS Survival (mo) Relative Risk Cisplatin/ cyclophosphamide Cisplatin/paclitaxel McGuire WP, et al. N Engl J Med. 1996;334:1-6.
9 GOG0182-ICON5: Schema I Carboplatin AUC 6 (d1) Paclitaxel 175 mg/m2 (d1) x8 R A N D O M I Z E II III IV V Carboplatin AUC 5 (d1) Paclitaxel 175 mg/m 2 (d1) Gemcitabine 800 mg/m 2 (d1,8) Carboplatin AUC 5 (d1) Paclitaxel 175 mg/m 2 (d1) Doxil 30 mg/m 2 (d1, every other cycle) Carboplatin AUC 5 (d3) Topotecan 1.25 mg/m 2 (d1-3) Carboplatin AUC 6 (d8) Gemcitabine 1 g/m 2 (d1,8) x4 x4 x8 x8 Carboplatin AUC 6 (d1) Paclitaxel 175 mg/m 2 (d1) x4 JCO 2008
10 GOG0182-ICON5: Progression-Free Survival
11 GOG0182-ICON5: Overall Survival
12 Primary Therapy IP Median PFS, months Hazard ratio Median OS, months Hazard ratio GOG GOG GOG IV IP (P =.01) 0.80 (P =.05) IV IP (P =.02) 0.81 (P =.05) 0.75 (P =.03) PFS = Progression-free survival; OS = Overall survival; IV = Intravenous; IP = Intraperitoneal. 1. Alberts DS, et al. N Engl J Med. 1996;335: Markman M, et al. J Clin Oncol. 2001;19: Armstrong DK, et al. N Engl J Med. 2006;354:34-43.
13 GOG #172 Armstrong et.al. N Engl J Med 2006;354:34-43 BRCA Analysis DNA Banking Second look Laparotomy (if chosen) Ovarian cancer Optimal (<1cm) Stage III Stratify: Gross residual Planned 2 nd look R A N D O M I Z E Paclitaxel 135 mg/m 2 /24h Cisplatin 75 mg/m 2 q 21 days x 6 Paclitaxel 135 mg/m 2 /24h Cisplatin 100 mg/m 2 IP D2 Paclitaxel 60 mg/m 2 IP D8 q 21 days x 6
14 GOG #172: outcomes Regimen 1 Intravenous Regimen 2 Intraperitoneal Progression-free 18.3 mos 23.8 mos Overall Survival 49.5 mos 66.9 mos
15 Figure 1 By Treatment Group (GOG 172) 1.0 Proportion Progression-Free months for IV Rx Group PF Failed Total IV IP months for IP group (Δ = 6 months) Months on Study
16 GOG Protocol 172 By Treatment Group IP median overall survival = 66 months (Δ = 16 months) Proportion Surviving IV median overall survival = 49.5 months Rx Group Lost to Alive Dead Total Follow-up Rx IV Group 5 Alive Dead 78 Total IV IP Months on Study N Engl J Med. 2006;354: Relative risk of death = 0.75 (95% CI: 0.58, 0.97) P =.03
17 GOG Protocol 172 Toxicity G3/4 G3/4 G3/4 G3/4 G3/4 G3/4 G3/4 G3/4 G3/4 Leukopenia* Platelet GI* Renal* Neurologic Event* Fatigue* Infection* Metabolic* Pain* IV, % (N = 210) IP, % (N = 201) *P 0.05
18
19 Modulating Toxicity of IP Therapy New approaches to improve toxicity profile Timing of catheter placement Timing of chemotherapy relative to surgery relative to catheter placement Agents used Supportive care (anti-emetics, IV fluids, myeloid growth factor) Successful use of IP therapy requires: Training Skill Experience Dedication
20 GOG 252: Newest upfront IP study
21 IGCS Bangkok October 25 th 2008
22 Ovarian, tubal or peritonal cancer FIGO stage IIIc-IV (n = 718) Randomisation Primary Debulking Surgery Neoadjuvant chemotherapy 3 x Platinum based CT 3 x Platinum based CT Interval debulking (not obligatory) Interval debulking if no PD > 3 x Platinum based CT > 3 x Platinum based CT Primary Endpoint: Overall survival Secondary endpoints: Progression Free Survival, Quality of Life, Complications
23 Randomised EORTC-GCG/NCIC GCG/NCIC-CTG CTG trial on NACT + IDS versus PDS Statistical considerations 704 patients were required in order to show noninferiority with respect to survival between PDS and NACT, with a one-sided type I error of 0.05 and a power of 80%.
24 Randomised EORTC-GCG/NCIC GCG/NCIC-CTG CTG trial on NACT + IDS versus PDS Baseline Characteristics (ITT) PDS NACT -> > IDS FIGO Stage IIIc IV 77% 23% 77% 23% Serous 64% 58% Age 62 (25-86) 62 (33-81) CA125 > 30 KU/L 98% 99% Largest metastasis (mm) 80 (0-400) 80 (0-389)
25 Randomised EORTC-GCG/NCIC GCG/NCIC-CTG CTG trial on NACT + IDS versus PDS Surgical findings and results (PP1) PDS (n = 329) NACT -> > IDS (n = 339)* Metastases before > 2 cm 95% 68% Metastases before > 10 cm 62% 27% No residual after surgery 21% 53% 1 cm after surgery 46% 82% * % calculated on the 306 patients who underwent IDS.
26 Randomised EORTC-GCG/NCIC GCG/NCIC-CTG CTG trial on NACT + IDS versus PDS Surgical characteristics (PP1) Postoperative mortality (< 28 days) PDS (n = 329) NACT -> > IDS (n = 339)* 2.7% 0.6% Postoperative fever Gr % 2% Fistula (bowel/gu) 1.2% / 0.3% 0,3% / 0.6% Operative time (minutes) Red blood cell transfusion 51% 53% Hemorhage Grade 3/4 7% 1% Venous Gr 3/4 2.4% 0.3%
27 NACT + IDS versus PDS: ITT Progression-free survival Median PFS PDS: 12 months IDS: 12 months HR for IDS:0.99 (0.87, 1.13) 0 (years) O N Number of patients at risk : Treatment Upfront debu Neoadjuvant
28 NACT + IDS versus PDS: ITT Overall survival Median survial PDS: 29 months IDS: 30 months HR for IDS:0.98 (0.85, 1.14) (years) O N Number of patients at risk : Treatment Upfront debulking s Neoadjuvant chemo
29 NACT + IDS versus PDS: ITT Survival time: Figo stage EORTC Events / Patients Statistics Upfront debulkingneo-adj. Chemo (O-E) Var. HR & CI* (Upfront debulking : Neo-adj. Chemo) 1-HR % ± SD III 190 / / IV 68 / / Total 258/ / (72.3 %) (70.2 %) 2% ±9 increase Test for heterogeneity Chi-square=0.5, df=1: p> Upfront debulking Neo-adj. Chemo better better Treatment effect: p>0.1 *90% CI everywhere
30 NACT + IDS versus PDS: ITT Survival time: Age EORTC Events / Patients Upfront debulkingneo-adj. Chemo Statistics (O-E) Var. HR & CI* (Upfront debulking : Neo-adj. Chemo) 1-HR % ± SD <50 34 / / / / >70 53 / / Total 259/ / (71.7 %) (70.3 %) 3% ±9 increase Test for heterogeneity Chi-square=2.59, df=2: p> Upfront debulking Neo-adj. Chemo better better Treatment effect: p>0.1 *90% CI everywhere
31 Multivariate analysis for OS(PP1) P values Optimal debulking Histological type (9 categories) Largest tumor size at randomisation Figo Stage (IIIc vs IV) Country (14 categories) Age WHO PS Differentiation Grade Treatment arm NS NS NS
32 Conclusions 1. In Stage IIIc-IV IV OVCA, NACT followed IDS produces similar OS and PFS outcomes compared to standard primary debulking followed by chemotherapy in FIGO Stage IIIc-IV IV ovarian carcinoma. 2. There does not seem to be a subgroup based on 1. Stage IIIc or IV 2. Age 3. WHO performance 4. Histological type ovarian cancer 5. Countries with high or low optimal debulking rate for which PDS or NACT -> > IDS result in better survival. Because of the overall poorer PFS and OS compared to other studies, the use of neoadjuvant chemotherapy is not considered the standard of care in the United States, but is reserved for patients who are too ill to undergo initial surgery or those patients who have clearly non-debulkable cancer.
33 PFS and OS for newly diagnosed advanced ovarian cancer Study Median PFS Median OS Comments GOG 111 NEJM mos 38 mos Suboptimally and stage IV GOG 158 JCO mos 57.4 mos Optimally cytoreduced only GOG 172 NEJM mos 65 mos Optimally cytoreduced only. Longest survival observed in advanced ovarian cancer GOG 182 JCO mos 44 mos Both optimal and suboptimal. Study compared 5 arms of treatment Weekly pac vs q21 d Lancet mos (vs. 17 mos) Not reached Both optimal and suboptimal EORTC neoadjuvant IGCS 2008 Both 12 mos 29/30 mos Neoadjuvant vs. upfront debulking GOG 218: ASCO 2010
34 Dose dense paclitaxel versus q 3 week paclitaxel for newly diagnosed ovarian cancer 631 eligible patients were enrolled Eligibility: stage II to IV epithelial ovarian cancer Pts could have upfront or interval debulking surgery Primary endpoint was PFS Treatment 1 : Paclitaxel 180 mg/m2 + carboplatin AUC 6 day both day 1 or Paclitaxel 80 mg/m2 days 1, 8, 15 + carboplatin AUC 6 day 1 (dose dense group) 1 Creatinine clearance calculated by Jelliffe and treatment given for 6 cycles Katsumata et al, Lancet 2009
35 Progression-free survival PFS for: DD Pac: 28 months q3 week: 17.2 mos HR 0.75 (95% CI: ) p=0.015 Katsumata et al, Lancet 2009
36 Overall survival 3 year OS for: DD Pac 72% q3 week: 65% HR 0.75 (95% CI: ) p=0.03 Katsumata et al, Lancet 2009
37 Progression-free survival according to baseline characteristics Lancet, 2009
38 Grade 3/4 anemia was higher in the dose dense group From: Katsumata et al, Lancet 2009
39 GOG Frontline Trials GOG-218 Optimal or Suboptimal EOC, PPC, FT cancer Paclitaxel Carboplatin Placebo Paclitaxel Carboplatin Bevacizumab Paclitaxel Carboplatin Bevacizumab Placebo 15 months Placebo 15 months Bevacizumab 15 months Survival, PFS primary endpoints Biologic & QOL endpoints EOC = Epithelial ovarian cancer; PPC = Primary peritoneal cancer; FT = Fallopian tube; PFS = Progression-free survival; QOL = Quality of life.
40 GOG 218 results To be presented at ASCO 2010 Preliminary results were released via press release in March 2010 ( Patients receiving carboplatin/taxol/bevacizumab + bevacizumab maintenance did better than carbo/taxol alone. Patients receiving carboplatin/taxol/bevacizumab (no maintenance) did equally well as patients receiving carboplatin/taxol alone. At this point, our group is not using bevacizumab off study.
41 Newer biologics being added to upfront treatment PARP inhibitors Src inhibitors Other anti-angiogenics angiogenics besides bevacizumab Notch inhibitors
42 Protocol Pilot study screening for druggable mutations in both recurrent and newly diagnosed advanced ovarian cancer. Opened March 2010; 28 pts enrolled thus far. CLIA-approved PIK3CA, KRAS,, and BRAF testing at LMM (for clinical decision making). OncoMap platform used thereafter to test for 1100 mutations in 100 oncogenes (for research).
43 Standard of Care for pts with advanced epithelial ovarian cancer: 2010 Upfront debulking surgery by a gynecologic oncologist. If optimally cytoreduced (i.e. 1cm tumor remaining), options are: Placement of an IP port and IP/IV tx 1, IV carboplatin/paclitaxel,, or clinical trial. If suboptimally cytoreduced,, options are: IV carboplatin/paclitaxel (q3 week or weekly paclitaxel) 3 or clinical trial Neoadjuvant chemotherapy 2 has demonstrated equivalent results to upfront cytoreduction chemotherapy, but this appears more popular in Europe than the U.S. with lower OS and PFS overall compared to other studies. 1 Armstrong DK, et al, N Engl J Med 354(1):34-43, Vergote I et al. IGCS 2008 Meeting: Abstract #2008_1767. Available at: 3
44 Following completion of upfront chemotherapy CA125 monitoring every 3 months; although off study, controversy exists whether or not this is of benefit 1 Several drugs are being tested in the first maintenance setting. There is no standard of care for use of maintenance therapy 2 1 Rustin GJ et al, J Clin Oncol 27(18s):Abstr 1, Foster et al, Gyn Onc 115: , 2009
45 Conclusions Standard of care for newly diagnosed advanced ovarian, tubal or peritoneal cancer remains a platinum and taxane combination New options for patients include dose dense administration of paclitaxel Results of GOG 218 asking question of role of bevacizumab in newly diagnosed patients to be presented at ASCO 2010
Jemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationOVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)
1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationOvarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?
Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationReview Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationGranulosa Cell Tumor Monitoring and Treatment. Outline: 1. Surgery 2. Adjuvant 3. Chemo 4. Hormonal 5. Investigational. Whole Genome Sequencing
Potential Conflicts of Interest capped at a level befitting an academic role Lo B. Serving Two Masters 2010;362:669-671 Granulosa Cell Tumor Monitoring and Treatment Richard T. Penson, MD, MRCP Clinical
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationSurvival impact of cytoreductive surgery ın advanced stage EOC
Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationOVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 OVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationAHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following
AHFS Final Determination of Medical Acceptance: Off-label Use of Sequential IV Paclitaxel, Intraperitoneal Cisplatin, and Intraperitoneal Paclitaxel for Initial Adjuvan nt Treatment of Optimally Debulked
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationBreakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics
Breakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics CLAUDIO CALAZAN Oncologia D Or Oncologistas Associados First-line treatment : The role of anti angiogenics
More informationExpert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair. December 13, 2016
Expert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair December 13, 2016 1 Forward-Looking Statements This presentation includes forward-looking statements based on management's
More informationRANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED
RANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED CHEMOTHERAPY FOR HIGH- RISK STAGE I AND STAGE II-IV OVARIAN
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationU T C H. No disclosure
D U GOG T C H Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer: OVHIPEC-2 Willemien van
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationEligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment
Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Radiology and Oncology Ljubljana Slovenia www.radioloncol.com research article 341 The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Erik Škof 1, Sebastjan
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 1 JANUARY 1 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer:
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationHow to fight a silent killer: Lessons learned from Ovarian Cancer. Stephen A. Cannistra, M.D.
How to fight a silent killer: Lessons learned from Ovarian Cancer Stephen A. Cannistra, M.D. How to fight a silent killer: Lessons learned from Ovarian Cancer Ovarian cancer is not common but is highly
More informationBackground. TAP, Paclitaxel + Doxorubicin + Cisplatin
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage
More informationOriginal Research. Open Access
To cite: Milani A, Kristeleit R, McCormack M, et al. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 24 AUGUST 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter
More informationsymposium article Optimal primary therapy of ovarian cancer M. A. Bookman* introduction symposium article
Annals of Oncology 27 (Supplement 1): i58 i62, 2016 doi:10.1093/annonc/mdw088 Optimal primary therapy of ovarian cancer M. A. Bookman* Arizona Oncology and US Oncology Research, Tucson, AZ, USA Background:
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationA Phase 2 Trial of Voreloxin (SNS-595) in Platinum - Resistant Epithelial Ovarian Cancer
A Phase Trial of Voreloxin (SNS-595) in Platinum - Resistant Epithelial varian Cancer William McGuire, M.D. Medical Director Harry and Jeanette Weinberg Cancer Institute November 6, 008 1 Voreloxin: First-In-Class
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationAvastin NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. bevacizumab (rch)
NAME OF THE MEDICINE Avastin bevacizumab (rch) CAS 216974-75-3 Bevacizumab is an immunoglobulin G (IgG) composed of two identical light chains, consisting of 214 amino acid residues and two 453 residue
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationA Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and
Randomized study of sequential cisplatintopotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationDr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant Medical Oncologist
Title: Systemic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer Author(s) Ownership: Approval by: Operational Date: Dr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationDATE: 22 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Intraperitoneal versus Intravenous Chemotherapy for the Treatment of Ovarian Cancer: A Review of the Comparative Clinical Evidence, Safety, Cost- Effectiveness, and Guidelines DATE: 22 May 2013
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationGynecologic Oncology
Gynecologic Oncology 124 (2012) 10 14 Contents lists available at SciVerse ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno An analysis of patients with bulky advanced
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More information